Carole Ben-Maimon - 26 Jan 2026 Form 4 Insider Report for Larimar Therapeutics, Inc. (LRMR)

Role
President and CEO, Director
Signature
/s/ Jennifer Johansson, Attorney-in-fact
Issuer symbol
LRMR
Transactions as of
26 Jan 2026
Net transactions value
$0
Form type
4
Filing time
27 Jan 2026, 17:04:08 UTC
Previous filing
24 Jan 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
BEN-MAIMON CAROLE President and CEO, Director C/O LARIMAR THERAPEUTICS, INC., THREE BALA PLAZA EAST, SUITE 506, BALA CYNWYD /s/ Jennifer Johansson, Attorney-in-fact 27 Jan 2026 0001529611

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LRMR Common Stock Award $0 +100,100 +37% $0.000000 368,276 26 Jan 2026 Direct F1
holding LRMR Common Stock 31,155 26 Jan 2026 By Trust F2
holding LRMR Common Stock 31,155 26 Jan 2026 By Trust F3
holding LRMR Common Stock 31,156 26 Jan 2026 By Trust F4
holding LRMR Common Stock 31,156 26 Jan 2026 By Trust F5
holding LRMR Common Stock 31,156 26 Jan 2026 By Trust F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LRMR Stock Option (Right to Buy) Award $0 +600,600 $0.000000 600,600 26 Jan 2026 Common Stock 600,600 $3.60 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
F2 Represents shares held by the Irrevocable Deed of Trust of Carole S. Ben-Maimon for the Benefit of Meadow Lainey Ben-Maimon ("Meadow Trust"), of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of the shares held by the Meadow Trust except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed to be an admission that she has beneficial ownership of such shares for Section 16 or any other purpose.
F3 Represents shares held by the Irrevocable Deed of Trust of Carole S. Ben-Maimon for the Benefit of Olivia Liat Stein ("Olivia Trust"), of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of the shares held by the Olivia Trust except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed to be an admission that she has beneficial ownership of such shares for Section 16 or any other purpose.
F4 Represents shares held by the Irrevocable Deed of Trust of Carole S. Ben-Maimon for the Benefit of Ella Bar Stein ("Ella Trust"), of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of the shares held by the Ella Trust except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed to be an admission that she has beneficial ownership of such shares for Section 16 or any other purpose.
F5 Represents shares held by the Irrevocable Deed of Trust of Carole S. Ben-Maimon for the Benefit of Romi Aleeza Stein ("Romi Trust"), of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of the shares held by the Romi Trust except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed to be an admission that she has beneficial ownership of such shares for Section 16 or any other purpose.
F6 Represents shares held by the Irrevocable Deed of Trust of Carole S. Ben-Maimon for the Benefit of Matzi Mark Ben-Maimon ("Matzi Trust"), of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of the shares held by the Matzi Trust except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed to be an admission that she has beneficial ownership of such shares for Section 16 or any other purpose.
F7 The option vests 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.